How to continue Strattera after moving to Illinois

If you’re exploring ADHD treatment options, you’ve likely come across telehealth as a convenient way to get care—especially if you live in an area with limited access to specialists or simply prefer the flexibility of virtual appointments. But can you actually get ADHD medication, particularly non-stimulant options like Strattera, through a video visit? The short answer: Yes, in most cases you can. In fact, telehealth has opened new doors for people seeking effective, accessible ADHD treatment without the hassle of in-person visits.

Understanding the rules around telehealth prescribing for ADHD medications can feel overwhelming, especially with evolving federal and state regulations. This guide will walk you through everything you need to know about getting non-stimulant ADHD medication via telehealth in 2025—including how it works, what the current laws say, and what to expect from your virtual visit.

Understanding ADHD Non-Stimulant Medications

Before diving into telehealth specifics, let’s clarify what we mean by ‘non-stimulant’ ADHD medications. While stimulant medications like Adderall and Ritalin are the most commonly prescribed ADHD treatments, non-stimulants offer an important alternative—especially for people who can’t tolerate stimulants or have concerns about potential dependency.

Strattera (atomoxetine) is the most well-known non-stimulant ADHD medication. Unlike stimulants, Strattera is not a controlled substance under federal law, which has significant implications for how it can be prescribed via telehealth. Other non-stimulant options include Qelbree (viloxazine), Intuniv (guanfacine), and Kapvay (clonidine).

The key advantage of non-stimulants from a telehealth perspective? They’re not subject to the Drug Enforcement Administration’s (DEA) special prescribing requirements that apply to controlled substances. This means no mandatory in-person exam is required at the federal level, making them more accessible through virtual care platforms.

How Non-Stimulants Work Differently

Non-stimulant ADHD medications work through different mechanisms than stimulants:

• Strattera increases norepinephrine levels in the brain, which helps with attention and impulse control
• Unlike stimulants, non-stimulants typically take 4-6 weeks to reach full effectiveness
• They provide 24-hour coverage without the ‘wearing off’ effect some people experience with stimulants
• There’s no risk of dependency or abuse, making them ideal for people with a history of substance use concerns

Non-stimulants are often prescribed when stimulants cause unacceptable side effects (like anxiety, sleep problems, or appetite suppression), when there’s a personal or family history of addiction, or when patients have certain medical conditions like uncontrolled high blood pressure or heart problems.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

The Current State of Telehealth for ADHD Treatment

The landscape of telehealth ADHD care has evolved dramatically over the past few years. During the COVID-19 pandemic, emergency rules allowed providers to prescribe controlled substances (including ADHD stimulants) via telehealth without a prior in-person exam. As of December 2025, these flexibilities have been extended through December 31, 2025, allowing continued telehealth access to both stimulant and non-stimulant ADHD medications.

Federal Rules: What the DEA Says

The DEA has issued a ‘Third Temporary Extension’ of COVID-era telehealth prescribing rules, which permits healthcare providers to prescribe Schedule II-V controlled substances (including ADHD stimulants) via telehealth through the end of 2025. However, it’s important to note:

• These are temporary rules that could change in 2026
• A fourth extension or new permanent framework is anticipated but not yet finalized
• The DEA is working on a proposed ‘Special Registration’ system that might create permanent telehealth pathways with additional safeguards

For non-stimulant medications like Strattera, the situation is much clearer and more stable. Since these medications aren’t controlled substances, they don’t fall under the Ryan Haight Act’s in-person examination requirement. This means telehealth prescribing of non-stimulants has been—and continues to be—fully legal under federal law, with no special restrictions beyond standard medical practice requirements.

Why This Matters for Patients

If you’re considering non-stimulant ADHD treatment, the regulatory environment is actually quite favorable for telehealth access:

• No federal mandate for an initial in-person visit
• 90-day supplies can typically be prescribed (unlike the 30-day limit for stimulants)
• Refills can be authorized for up to a year in most cases
• Less regulatory scrutiny compared to controlled substances

That said, state laws vary, and your telehealth provider must be licensed in your state and follow all applicable regulations.

State-by-State Telehealth Rules: What You Need to Know

While federal law sets the baseline, individual states have their own telehealth regulations that can be stricter. Here’s what you should know about key states:

States with Minimal Restrictions

California, Illinois, Pennsylvania, and Georgia have embraced telehealth with few additional barriers for non-controlled medications. In these states, a comprehensive video evaluation can establish a doctor-patient relationship, and providers can prescribe Strattera or other non-stimulants without requiring any in-person visits.

New Hampshire recently updated its laws in August 2025 to remove previous in-person requirements, making it much easier to access ADHD treatment via telehealth. The state now only requires at least one annual follow-up evaluation (which can be conducted via telehealth) for ongoing controlled substance prescriptions.

States with Additional Requirements

Florida has specific rules around Schedule II controlled substances (stimulants), prohibiting telehealth prescribing unless the medication is for a psychiatric condition—which ADHD qualifies as. For non-stimulants like Strattera, Florida imposes no special restrictions, and telehealth prescribing is straightforward.

Alabama stands out as one of the strictest states for telehealth. The state requires an in-person visit within 12 months for ongoing telehealth treatment, though there’s an important exception: mental health services are exempt from this rule. Since ADHD is considered a mental health condition, you may be able to receive ongoing telehealth care without the annual in-person requirement. However, Alabama also has unique rules about having a nurse or medical professional physically present with you during certain telehealth visits for controlled substances—though this doesn’t apply to non-controlled Strattera.

New York reinstated an in-person prerequisite in 2025 for prescribing any controlled substance via telemedicine. This affects stimulant prescriptions, requiring an initial in-person evaluation. However, non-controlled medications like Strattera can still be prescribed via telehealth without an in-person visit, since the rule specifically targets controlled drugs.

Texas is generally telehealth-friendly for mental health care, with no blanket in-person requirement for ADHD treatment. The main Texas quirk involves prescriber types: Nurse Practitioners and Physician Assistants can’t prescribe Schedule II stimulants unless working in hospital or hospice settings, though physicians face no such restriction. For Strattera (non-controlled), both MDs and NPs/PAs can prescribe via telehealth under appropriate supervision agreements.

Who Can Prescribe ADHD Medications Via Telehealth?

The type of provider who can prescribe your ADHD medication via telehealth depends on both the medication type and your state’s laws.

Physicians (MD/DO)

Licensed physicians in all states can prescribe both stimulant and non-stimulant ADHD medications via telehealth, provided they:

• Hold an active medical license in your state
• Have a valid DEA registration (for controlled substances)
• Follow standard diagnostic and prescribing practices
• Comply with state-specific telehealth regulations

Nurse Practitioners (NPs) and Physician Assistants (PAs)

The authority of NPs and PAs to prescribe ADHD medications varies significantly by state:

Full Practice Authority States: In states like New York, Illinois, New Hampshire, and California, NPs can practice independently and prescribe controlled substances (including stimulants) after meeting certain experience requirements. California’s AB 890 allows NP independent practice after meeting experience thresholds, while New York removed written practice agreement requirements in 2022 after NPs complete 3,600 hours of supervised practice.

Collaborative Practice States: States like Florida, Pennsylvania, and Texas require NPs and PAs to have a collaborative agreement with a supervising physician. In these states:

• Non-controlled medications (like Strattera) can be prescribed with proper collaboration
• Controlled substance prescribing authority varies—some states allow it with physician delegation, others don’t
• Texas notably restricts NP/PA Schedule II prescribing to hospital and hospice settings only

Restricted States: Georgia stands out as prohibiting NPs from prescribing Schedule II drugs at all, even under physician supervision. In these states, if you want stimulant medication, you’ll need to see an MD or DO. However, NPs can still prescribe non-stimulants like Strattera under collaborative agreements.

What this means for you: When choosing a telehealth platform like Klarity Health, the service will match you with an appropriately licensed provider in your state who can legally prescribe the medications you need. Klarity’s network includes both physicians and advanced practice providers, ensuring you have access to care regardless of your state’s specific requirements.

How Telehealth ADHD Evaluations Work

Getting an ADHD diagnosis and prescription via telehealth isn’t as simple as answering a few questions online. Legitimate telehealth providers follow rigorous evaluation protocols that mirror in-person assessments.

What to Expect During Your Initial Visit

A comprehensive telehealth ADHD evaluation typically includes:

Detailed Clinical Interview: Your provider will ask about:

• Current symptoms and how they affect your work, relationships, and daily life
• Childhood symptoms (ADHD must have onset before age 12 according to DSM-5 criteria)
• Medical history, including other mental health conditions
• Medication history and any previous ADHD treatments
• Family history of ADHD or other psychiatric conditions
• Substance use history (past and present)

Standardized Assessment Tools: Many providers use validated rating scales like:

• Adult ADHD Self-Report Scale (ASRS)
• Conners’ Adult ADHD Rating Scales
• Childhood symptom questionnaires

Functional Impairment Assessment: Your provider needs to document that symptoms cause significant problems in multiple settings (not just at work or just at home). They may ask for input from family members or request documentation like old report cards or performance reviews.

Medical Screening: Before prescribing any ADHD medication, your provider will:

• Review your cardiovascular health (heart rate, blood pressure history)
• Screen for contraindications specific to the medication being considered
• Ask about other medications you take to check for interactions
• For Strattera specifically: check for narrow-angle glaucoma, liver problems, and recent MAOI use

Treatment Plan Discussion: If ADHD is confirmed, your provider will:

• Explain medication options (stimulant vs. non-stimulant)
• Discuss expected benefits and potential side effects
• Set realistic expectations (e.g., Strattera takes 4-6 weeks to work fully)
• Create a follow-up schedule to monitor response

Documentation You Might Need

To strengthen your evaluation and speed up the process, consider gathering:

• Previous ADHD diagnoses or psychological testing reports
• School records showing academic struggles (if available)
• List of current medications and dosages
• Summary of past ADHD treatments and their effectiveness
• Any relevant medical records (especially cardiac history)

Red Flags That Might Exclude You from Telehealth Treatment

Reputable providers screen carefully for situations where telehealth may not be appropriate:

Medical Contraindications:

• Uncontrolled high blood pressure or serious heart conditions requiring specialist management
• Active substance use disorder (though history of past substance abuse doesn’t automatically disqualify you—non-stimulants may be preferred)
• Severe, unstable mental health conditions like uncontrolled bipolar disorder or active psychosis
• Certain medical conditions that contraindicate specific medications (e.g., narrow-angle glaucoma for Strattera)

Diagnostic Complexity:

• Symptoms that could indicate multiple overlapping conditions requiring in-person specialist evaluation
• Very young children (most telehealth platforms have minimum age requirements, often 18+)
• Situations requiring in-person cognitive testing or neurological examination

Behavioral Red Flags:

• Requesting specific controlled substances by name without completing evaluation
• Seeking early refills or unusually high doses
• ‘Doctor shopping’ patterns visible in prescription monitoring databases
• Refusing to consent to PDMP checks or communication with other healthcare providers
• Inconsistent symptom reporting

If your situation is complex, your telehealth provider might recommend starting with a non-stimulant medication like Strattera (which has less abuse potential) or refer you for an in-person specialist evaluation before proceeding with controlled stimulants.

Strattera and Other Non-Stimulants: The Telehealth Advantage

Non-stimulant ADHD medications offer several advantages in the telehealth context:

Regulatory Simplicity

Since Strattera isn’t a controlled substance, prescribing it via telehealth involves:

• No DEA restrictions on initial prescribing
• No mandatory in-person exam under federal law
• Longer prescription periods possible (often 90-day supplies with multiple refills)
• Electronic prescribing without special DEA e-prescribing requirements
• Less pharmacy scrutiny compared to stimulant prescriptions

Clinical Benefits for Certain Patients

Non-stimulants may be the preferred choice if you:

• Have a personal or family history of substance abuse
• Experience anxiety that worsens with stimulants
• Have cardiovascular concerns (though Strattera still requires blood pressure monitoring)
• Need 24-hour symptom coverage without the peaks and valleys of stimulants
• Prefer to avoid controlled substances for personal, professional, or legal reasons
• Have had negative experiences with stimulant side effects

What to Know About Strattera Specifically

How it works: Strattera (atomoxetine) is a selective norepinephrine reuptake inhibitor. It increases norepinephrine in the brain, which helps with attention, impulse control, and executive function.

Timeline: Unlike stimulants that work within hours, Strattera typically takes:

• 1-2 weeks to notice initial effects
• 4-6 weeks to reach full therapeutic benefit
• Some people see continued improvement over 3 months

Dosing: Starting dose is usually low (25-40mg daily) and increased gradually to minimize side effects. Target dose is often 80-100mg daily for adults, though this varies by individual response and weight.

Side effects to monitor with your telehealth provider:

• Initial: Upset stomach, decreased appetite, dry mouth, dizziness
• Ongoing: Blood pressure and heart rate increases (monitored at follow-ups)
• Rare but serious: Liver problems (requires monitoring if symptoms develop), increased suicidal thoughts in young people (requires close monitoring, especially initially)

Follow-up schedule: Expect video visits:

• 2-4 weeks after starting to assess tolerance and initial response
• Every 4-8 weeks during dose adjustment
• Every 3 months once stable
• Blood pressure checks can be done at local pharmacies or with home monitors

Other Non-Stimulant Options

Qelbree (viloxazine): A newer non-stimulant approved in 2021, also not controlled. Works similarly to Strattera but may have a slightly different side effect profile.

Intuniv (guanfacine) and Kapvay (clonidine): Originally blood pressure medications, these are sometimes used for ADHD, particularly for hyperactivity and impulsivity. They can cause drowsiness and are sometimes used to help with sleep issues in ADHD.

Your telehealth provider will discuss which option might be best based on your specific symptom profile, medical history, and treatment goals.

Prescription Monitoring and Safety Measures

Even though non-stimulants aren’t controlled substances, legitimate telehealth providers implement several safety measures:

Prescription Monitoring Programs (PMPs)

While not legally required for Strattera, many providers check your state’s Prescription Drug Monitoring Program (PDMP) anyway to:

• Review your controlled substance prescription history
• Identify potential drug interactions
• Ensure coordinated care if you’re seeing multiple providers
• Screen for patterns that might indicate substance misuse

States vary in their PDMP requirements:

• Florida requires PDMP checks before every controlled substance prescription
• California mandates checks at least every 4 months for ongoing controlled therapy
• Pennsylvania requires checking before the first opioid or benzodiazepine prescription and every 90 days thereafter
• New Hampshire requires PDMP checks for each controlled substance prescription

Even when not legally mandated for non-controlled medications, checking the PDMP is considered good clinical practice.

Ongoing Monitoring and Follow-Up

Responsible telehealth ADHD care includes:

Regular Check-ins: Most providers schedule follow-up visits every 1-3 months, especially during the first six months of treatment.

Symptom Tracking: You may be asked to complete rating scales periodically to objectively measure treatment response.

Side Effect Monitoring: Your provider will check for:

• Blood pressure and heart rate changes (you may need to provide readings from home or local pharmacy)
• Liver function concerns (rare with Strattera, but important to watch for symptoms like unusual fatigue or yellowing skin)
• Mood changes or emergence of suicidal thoughts (particularly important in young adults)

Medication Adjustments: Based on response and side effects, your provider may:

• Increase dose if benefits are suboptimal and you’re tolerating medication well
• Decrease dose if side effects are problematic
• Switch to a different non-stimulant
• Consider adding or switching to a stimulant if non-stimulants aren’t effective enough

Coordination of Care: Good telehealth providers will:

• Communicate with your primary care doctor (with your permission)
• Recommend therapy or coaching to complement medication
• Refer to specialists if needed (e.g., sleep medicine if insomnia is an issue, cardiology if cardiovascular concerns arise)

How Klarity Health Makes ADHD Treatment Accessible

Klarity Health offers a streamlined approach to ADHD evaluation and treatment that addresses many common barriers to care:

Flexible, Fast Access to Licensed Providers

One of the biggest challenges with traditional ADHD care is waiting weeks or months for a specialist appointment. Klarity connects you with licensed healthcare providers who can typically see you within days, not months. This is especially valuable if you’re:

• In an area with few psychiatrists or ADHD specialists
• Unable to take time off work for multiple in-person appointments
• Dealing with urgent symptoms affecting your job or relationships

Transparent Pricing and Insurance Options

Healthcare costs shouldn’t be a mystery. Klarity Health offers:

• Clear, upfront pricing so you know what to expect
• Insurance acceptance for most major plans
• Cash-pay options if you’re uninsured or prefer not to use insurance

This dual approach means you have options regardless of your insurance situation, making treatment more accessible.

Comprehensive Evaluation Process

Klarity doesn’t cut corners on diagnosis. The platform ensures:

• Licensed providers in your state conduct thorough evaluations
• DSM-5 diagnostic criteria are followed
• Comprehensive symptom assessment covers multiple life areas
• Medical screening identifies any contraindications

This rigorous approach protects both your safety and the integrity of the diagnostic process.

Ongoing Support and Medication Management

ADHD treatment isn’t ‘one and done.’ Klarity’s model includes:

• Regular follow-up visits to monitor response and adjust treatment
• Medication management including dose optimization
• Easy prescription refills sent electronically to your pharmacy
• Access to your provider between appointments if concerns arise

Holistic Treatment Approach

While medication can be highly effective for ADHD, it’s most powerful when combined with other strategies. Klarity providers can:

• Recommend therapy or coaching to develop coping skills
• Discuss lifestyle modifications (sleep, exercise, nutrition) that support ADHD management
• Provide resources for workplace or academic accommodations
• Connect you with additional support as needed

The convenience of telehealth doesn’t mean sacrificing quality or comprehensiveness of care—it simply means getting the same high standard of treatment without the hassle of in-person appointments.

What Happens at the Pharmacy?

Once your provider prescribes Strattera or another non-stimulant, the prescription is sent electronically to your chosen pharmacy. Here’s what you need to know:

E-Prescribing and Pharmacy Acceptance

Electronic prescribing (e-prescribing) is now standard and offers several advantages:

• Faster processing—your pharmacy receives the prescription within minutes
• Fewer errors compared to handwritten prescriptions
• Easier refill management

Most pharmacies readily fill telehealth prescriptions from licensed providers. However, in 2023-2024, some pharmacies became more cautious about ADHD stimulant prescriptions from certain online platforms due to regulatory scrutiny. This typically doesn’t affect non-stimulant prescriptions like Strattera, which aren’t controlled substances.

Tips for Smooth Pharmacy Experience

• Use the same pharmacy consistently: This builds a relationship and helps the pharmacist understand your medication history
• Have your provider information ready: Know your telehealth provider’s name, practice name, and contact information
• Check your insurance coverage: Verify that Strattera is covered under your plan, or ask about generic atomoxetine (usually much cheaper)
• Plan ahead for refills: Request refills a few days before you run out to account for any processing delays
• Communicate openly: If the pharmacist has questions about your telehealth prescription, provide your provider’s contact information so they can verify

Cost Considerations

Brand vs. Generic: Strattera is available as a generic (atomoxetine), which is significantly less expensive—often $30-50/month with insurance or at discount programs, compared to $300+ for brand name without insurance.

Insurance Coverage: Most insurance plans cover atomoxetine/Strattera, though you may need prior authorization. Your Klarity provider can help with this paperwork if needed.

Cash-Pay Options: If you’re paying out of pocket, ask about:

• Pharmacy discount cards (GoodRx, SingleCare, etc.)
• Manufacturer coupons (sometimes available for brand Strattera)
• 90-day supplies for better pricing (often cheaper per dose than 30-day fills)

Typical costs for generic atomoxetine without insurance:

• With discount card: $30-$60/month
• Without discount: $100-$200/month

Compare this to stimulants which can cost $200-400/month for brand versions even with some insurance.

Common Questions and Concerns

‘Will my employer or school know I’m getting ADHD treatment via telehealth?’

Your ADHD diagnosis and treatment are protected health information under HIPAA. Your telehealth provider cannot disclose this information without your written consent. If you need documentation for workplace or academic accommodations, your provider can provide it, but only at your request.

‘What if the medication doesn’t work?’

Not everyone responds to every ADHD medication. If Strattera doesn’t provide adequate symptom relief after an appropriate trial (usually 8-12 weeks at therapeutic dose), your provider has several options:

• Try a different non-stimulant (like Qelbree or guanfacine)
• Consider adding a stimulant medication (if appropriate and legal in your state via telehealth)
• Adjust the dose (sometimes going higher helps, if you’re tolerating the medication well)
• Combine medication with therapy or coaching
• Refer you to a specialist for further evaluation

This is why ongoing follow-up is so important—treatment can be adjusted based on your response.

‘Can I switch from a stimulant to Strattera via telehealth?’

Yes, if you’re currently on a stimulant but experiencing problematic side effects or want to try a non-stimulant, your telehealth provider can manage this transition. The switch typically involves:

• Gradually reducing the stimulant dose (if you’ve been on it long-term)
• Starting Strattera at a low dose and increasing gradually
• A transition period of 2-6 weeks where Strattera reaches effectiveness
• Close monitoring during the switch

Some people end up using both—a stimulant for work hours and Strattera for baseline coverage—though this depends on individual needs and response.

‘What if I’m planning to move to a different state?’

Telehealth licensure is state-specific, meaning your provider must be licensed in the state where you’re physically located at the time of service. If you’re moving:

• Inform your current provider as soon as possible
• They may be licensed in multiple states and can continue your care
• If not, they can help transition you to a provider in your new state
• Platforms like Klarity often have nationwide networks and can facilitate smooth transitions
• Try to get at least a 90-day prescription before moving to allow time for finding a new provider

‘Are telehealth ADHD prescriptions ‘real’ prescriptions?’

Absolutely. A prescription written by a licensed healthcare provider via telehealth has the same legal standing as one written during an in-person visit. The method of the visit (video vs. in-person) doesn’t change the legitimacy of the prescription—what matters is that:

• The provider is licensed in your state
• A proper evaluation was conducted
• The prescription meets standard medical practice and legal requirements

The Future of Telehealth ADHD Treatment

As we move into 2026, several developments may shape telehealth ADHD care:

Potential Regulatory Changes

DEA Rules: The current temporary extension of telehealth prescribing for controlled substances expires December 31, 2025. Three possible scenarios for 2026:

1. Fourth extension: The DEA could extend current flexibilities another year
2. New permanent rules: The proposed ‘Special Registration’ system might be finalized, creating permanent telehealth pathways with specific requirements
3. Return to Ryan Haight requirements: If no extension or new rule is adopted, in-person exams could be required again for stimulant prescriptions

Good news for non-stimulant patients: Regardless of what happens with controlled substance rules, Strattera and other non-stimulants will remain accessible via telehealth because they were never subject to these restrictions in the first place.

State Law Evolution

More states are moving toward permanent telehealth frameworks rather than temporary emergency rules:

• Expansion: States like New Hampshire recently removed in-person requirements, and others may follow
• Standardization: Industry groups are pushing for more consistent state rules to reduce confusion
• Safeguards: Expect continued emphasis on PDMP checks, regular follow-ups, and prescriber accountability

Technology Improvements

Telehealth platforms are becoming more sophisticated:

• Better diagnostic tools: AI-assisted screening and objective attention testing may supplement clinical interviews
• Integration: Improved coordination between telehealth providers, pharmacies, and primary care doctors
• Wearables: Some providers may incorporate data from fitness trackers or smart watches to monitor medication effects on sleep, heart rate, etc.

Continued Scrutiny and Quality Focus

Following the 2023 investigations into some ADHD telehealth companies, the industry has matured significantly. Expect:

• Higher standards: Reputable platforms have strengthened evaluation protocols
• Greater transparency: Clearer communication about diagnostic criteria and prescribing policies
• Better patient education: More emphasis on non-medication treatments and realistic expectations

This evolution ultimately benefits patients by ensuring telehealth ADHD care remains accessible while maintaining safety and quality standards.

Making the Decision: Is Telehealth ADHD Treatment Right for You?

Telehealth works exceptionally well for many people seeking ADHD diagnosis and treatment, but it’s not the only option. Consider telehealth if:

✅ You’re a good candidate if:

• You have difficulty accessing in-person specialists due to location, wait times, or schedule
• Your symptoms are causing functional impairment but you don’t have severe, uncontrolled medical or psychiatric conditions
• You’re comfortable with technology and have reliable internet for video visits
• You’re seeking evaluation for the first time or looking to restart treatment
• You prefer the convenience and often lower cost of virtual care
• You’re interested in non-stimulant medications or are appropriate for stimulants (under current rules)

❓ Consider in-person care if:

• You have complex medical conditions requiring in-person examination
• You’re experiencing severe psychiatric symptoms that need immediate, hands-on intervention
• You prefer face-to-face interaction with your provider
• You have a very young child who may benefit from in-person developmental assessment
• Your situation is diagnostically complex (multiple overlapping conditions)

For many people, a hybrid approach works well: Initial diagnosis and stabilization via telehealth, with occasional in-person visits for comprehensive physical exams or when specific situations arise.

Taking the Next Step

If you’re ready to explore ADHD treatment through telehealth, here’s how to get started:

1. Research Your Options

Look for telehealth platforms that:

• Use licensed providers in your state
• Have transparent pricing and insurance policies
• Follow evidence-based diagnostic protocols
• Offer ongoing medication management, not just one-time prescriptions
• Have positive reviews and established track records

2. Prepare for Your Evaluation

Gather relevant information:

• List your symptoms and how they affect different areas of your life
• Note when symptoms began (ADHD symptoms should be present from childhood)
• Collect any relevant documentation (old report cards, previous evaluations, etc.)
• List current medications and health conditions
• Write down questions you want to ask your provider

3. Schedule Your Appointment

With platforms like Klarity Health, you can typically:

• Complete an online intake form
• Choose an appointment time that works for your schedule
• Meet with a licensed provider via secure video
• Receive a diagnosis and treatment plan (if appropriate) during or shortly after your visit

4. Follow Through with Treatment

If medication is prescribed:

• Fill your prescription promptly
• Take it as directed (for Strattera, give it the full 4-6 weeks to assess effectiveness)
• Attend follow-up appointments
• Communicate openly with your provider about your response
• Implement non-medication strategies alongside medication

5. Stay Informed

Keep up with:

• Communications from your telehealth provider about any regulatory changes
• Your state’s telehealth laws, especially if you travel or plan to move
• New treatment options and research about ADHD management

The Bottom Line

Yes, you can get ADHD non-stimulant medication through telehealth, and in 2025, it’s easier and more accessible than ever. Non-stimulant medications like Strattera offer an effective treatment option that isn’t subject to the regulatory complexity surrounding controlled substances. This means:

• No federal in-person exam requirement
• Longer prescription periods and easier refills
• Less regulatory uncertainty about future access
• Effective treatment for ADHD without stimulant-related concerns

While telehealth regulations for controlled stimulants continue to evolve, non-stimulants remain a stable, accessible option for people seeking ADHD treatment through virtual care. The key is finding a reputable provider who conducts thorough evaluations, provides ongoing support, and follows all applicable regulations.

Klarity Health makes this process straightforward by connecting you with licensed providers, offering transparent pricing and insurance options, and supporting you throughout your treatment journey—all from the comfort of your home.

If ADHD symptoms are affecting your work, relationships, or quality of life, telehealth treatment could be the accessible solution you’ve been looking for. With proper evaluation, appropriate medication (whether stimulant or non-stimulant), and ongoing support, many people find significant improvement in their symptoms and functioning.

Ready to take the next step? Visit Klarity Health to schedule an evaluation with a licensed provider who can assess your symptoms, discuss treatment options including non-stimulant medications, and create a personalized plan that works for your life. With flexible appointment times, accepting both insurance and cash pay, and providers available when you need them, getting ADHD treatment has never been more accessible.

References and Sources

1. Fierce Healthcare. ‘DEA finalizes one-year extension of controlled substance prescribing via telehealth.’ November 2024. Source

2. McDermott Will & Emery. ‘DEA Signals Extension of Telemedicine Flexibilities for Controlled Substance Prescribing for 2026.’ December 2025. Source

3. Sheppard Mullin Healthcare Law Blog. ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions.’ National Law Review, August 15, 2025. Source

4. Medical News Today. ‘Is Strattera a Controlled Substance?’ January 14, 2025. Source

5. RxAgent. ‘The Telehealth Compliance Trap: What Practitioners Need to Know Before 2026.’ October 2025. Source

Research verified as of December 17, 2025. Regulations are subject to change; readers should verify current rules with their healthcare provider or state medical board.

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment